References
- Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med 2023;388:529-542.
- Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011;13 Suppl 1(Suppl 1):S3.
- Schmajuk G, Trivedi AN, Solomon DH, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011;305:480-486.
- Tatangelo M, Tomlinson G, Paterson JM, et al. Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage. JAMA Netw Open 2019;2:e1917053.
- Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376.
- Verstappen SMM. The impact of socio-economic status in rheumatoid arthritis. Rheumatology (Oxford) 2017;56:1051-1052.
- Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J Mol Sci 2018;19:1739.
- Kim HW, Lee YJ, Ha YJ, Lee EB, Lee YJ, Kang EH. Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency. Korean J Intern Med 2024;39:668-679.